Manage subscriptions

You can follow the discussion on New study on the use of erythropoietin stimulating agents in chronic kidney disease has made us evaluate the risk-benefit of ESA’s in CKD patients not on dialysis. without having to leave a comment. Cool, huh? Just enter your email address in the form here below and you’re all set.